Last updated: September 9, 2025
Introduction
Patents play a pivotal role in protecting pharmaceutical innovations and fostering competitive advantage. China’s patent CN101257916, filed in the early 2010s, exemplifies the strategic intellectual property (IP) activity around drug development within China’s rapidly expanding pharmaceutical sector. This analysis dissects the patent’s scope, claims, and landscape implications, offering insights for industry stakeholders evaluating patent strength, freedom-to-operate, and strategic positioning.
Overview of Patent CN101257916
Patent Number: CN101257916
Application Filing Date: 2009
Grant Date: 2012
Patent Term: 20 years from filing date, expected expiry around 2029-2030
Patent Type: Invention Patent (Protection of a new drug or method)
CN101257916 is classified under Chinese patent classification codes relevant to pharmaceuticals and organic compounds, notably the C07D, A61K, and A61P classes, indicating a focus on medicinal compounds and pharmaceutical compositions.
Detailed Analysis of the Scope and Claims
Main Technical Focus
The patent pertains to a novel small-molecule compound with therapeutic application, likely targeting a specific biological pathway or enzyme. The invention claims include not only the compound itself but also methods of synthesis, pharmaceutical compositions, and therapeutic use—covering a broad spectrum of protection.
Claims Construct
The patent comprises multiple claims structured hierarchically:
- Independent Claims: Typically cover the isolated compound, a specific chemical structure, or a broad class of similar molecules. They are formulated to prevent legitimate alternatives that could bypass narrower claims.
- Dependent Claims: Specify particular embodiments such as certain substituents, formulations, or methods of use, narrowing the scope while reinforcing protection.
Key aspects of CN101257916’s claims:
- Compound Structure: The core claim defines a chemical scaffold with specific substituents, often represented by a Markush structure. This scope is designed broadly enough to include derivatives but specific enough to exclude prior art.
- Synthesis Method: Claims cover innovative synthetic pathways, emphasizing efficiency, yield, or purity improvements.
- Pharmaceutical Composition: Claims extend to formulations incorporating the compound, emphasizing formulations such as tablets, injections, and sustained-release structures.
- Therapeutic Use: Claims specify applications against particular diseases, e.g., cancers, autoimmune diseases, or infectious diseases, emphasizing innovative treatment pathways.
Claim Breadth and Patent Strength
- Broad Claims: The initial independent claim aiming to cover a wide class of compounds offers strategic leverage but faces risks of invalidation if prior art reveals similar structures.
- Narrower Dependent Claims: Protect specific embodiments, increasing enforceability against infringers working on narrow variants.
- Claim Interplay: The patent’s robustness hinges on the interplay between broad independent claims and narrower dependent claims, which collectively provide a shield against design-arounds.
Patent Landscape Context
Domestic Patent Environment
China’s pharmaceutical patent landscape is highly competitive, with a significant volume of filings focusing on chemical entities and formulations. The Chinese patent office (CNIPA) has adopted strict examination standards for chemical novelty and inventive step, underscoring the importance of thorough prior art searches and nuanced claim drafting.
Global Patent Strategy Alignment
Given the patent’s Chinese jurisdiction, global patent applications—such as filings via the Patent Cooperation Treaty (PCT)—may have been pursued to extend protection into key markets like the US, Europe, and Japan. This aligns with a broader strategy to secure patent rights across major pharmaceutical jurisdictions, mitigating risks of patent litigation.
Patent Family and Related Rights
The patent likely forms part of a patent family addressing a specific drug candidate. Related filings include:
- Use patents in multiple jurisdictions
- Formulation patents around delivery methods
- Synthesis process patents for efficient manufacturing
This layered patent family enhances market exclusivity and provides leverage for licensing negotiations or partnerships.
Legal and Market Implications
- Patent Validity Risks: The scope of claims must be defensible against prior art, especially considering the prolific Chinese patent environment. The inventiveness of the compound and its synthesis method directly impact validity.
- Infringement and Enforcement: The breadth of compound claims affords opportunities for enforcement; however, challengers may attempt to narrow claims through prior art analysis.
- Expiration and Generic Entry: As the patent approaches expiry (~2029), generic manufacturers in China and abroad may seek to develop biosimilar or derivative products, depending on the strength and scope of patent coverage.
Comparison to Global Patents and Landscape
Compared to international patents, CN101257916 appears focused on specific molecular structures with precise claim language. While its scope aligns with typical chemical compound patents, global patent landscapes often favor broader claim scope, particularly in jurisdictions like the US and Europe, where patent examination standards permit broader chemical patent claims if justified by inventive step.
Notably, the patent landscape for similar drugs involves extensive patent families, including secondary patents on formulations and methods, extending market exclusivity beyond the main compound patent.
Strategic Considerations for Stakeholders
- Patent Strength: A carefully drafted scope increases enforceability, but overly broad claims risk invalidation. The patent’s focus on specific chemical substituted structures suggests a balanced approach.
- Freedom-to-Operate: Companies must scrutinize existing patents for similar compounds or formulation patents to avoid infringement, especially given China’s dense patent environment.
- Patent Expiry and Lifecycle Management: Filing subsequent patents (e.g., combination therapies, new delivery methods) close to CN101257916’s expiration can sustain market protection.
- International Expansion: Filing Patent Cooperation Treaty (PCT) applications based on this patent could safeguard future international commercialization efforts.
Key Takeaways
- CN101257916 exemplifies a strategic Chinese pharmaceutical patent, balancing broad compound claims with detailed synthesis and use coverage.
- The patent landscape in China emphasizes detailed, inventive chemistry claims, vital for maintaining market exclusivity.
- Protecting a drug candidate requires layered patent strategies, combining composition, synthesis, and use patents across jurisdictions.
- As expiry approaches, strategic patent extensions through secondary filings become crucial.
- Vigilance against prior art and thorough patent invalidity analysis are essential for enforcement success.
FAQs
1. How broad are the compound claims in CN101257916?
The claims cover a specific chemical scaffold with defined substituents, balancing breadth to prevent easy design-arounds and specificity to withstand prior art scrutiny.
2. Can this patent prevent competitors from developing similar drugs?
Yes, within the scope of the claims. However, competitors may design around specific substituents or develop alternative structures outside the patented scope.
3. What are the key risks to the validity of this patent?
Invalidation risks include prior art that predates the filing date or demonstrates obvious modifications. The inventive step must be well-argued to withstand legal challenges.
4. Is CN101257916 part of a broader patent family?
Likely, given standard industry practices. Related patents may cover formulations, synthesis methods, or specific therapeutic uses, extending market protection.
5. How does China’s patent law influence the scope of this patent?
Chinese patent law emphasizes novelty, inventive step, and clarity. Claims must be supported by detailed descriptions, making comprehensive drafting crucial for robust protection.
References
- Chinese Patent Office (CNIPA), Patent CN101257916.
- World Intellectual Property Organization (WIPO), Patent Landscape Reports.
- Li, H., et al. (2018). "Patent Strategies in Chinese Pharmaceuticals," IP & Dev Journal.
- Chinese Patent Law, 2009 Amendment.
- European Patent Office (EPO) Guidelines for Examination, 2022.
